The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna ...

Moderna announced this weekend that the Food and Drug Administration approved its lower-dose Covid-19 vaccine for adults 65 ...

NEXSPIKE becomes Moderna’s third FDA-approved product CAMBRIDGE, MA / ACCESS Newswire / May 31, 2025 / Moderna, Inc.

Moderna Inc. gained US approval for a new Covid vaccine for a narrower group of people, in the latest sign that regulators ...

In this July 19, 2022, a vial of Moderna COVID-19 vaccine rests on a table at an inoculation station in Jackson, ...

The Food and Drug Administration has approved Moderna's new COVID-19 vaccine, days after the federal government tightened ...

Moderna said mNEXSPIKE was approved by the FDA for use in adults aged 65 and up, as well as some individuals aged 12 to 64.

FDA approves Moderna’s mNEXSPIKE COVID-19 vaccine for high-risk groups Phase 3 trial shows mNEXSPIKE outperforms original ...

Jefferies analysts said the approval was largely expected and an “incremental positive” for Moderna amid questions about the ...

Moderna's new COVID vaccine approval targets a broader high-risk population, but the market remains skeptical due to limited revenue prospects and ongoing losses. Management is pivoting to cost ...

Moderna has announced the FDA approval of a new, lower-dose messenger RNA (mRNA) vaccine against COVID-19, called mNEXSPIKE (mRNA-1283) (1). The product joins Moderna’s original COVID vaccine, ...